Viral lymphomagenesis: From pathophysiology to the rationale for novel therapies

British Journal of Haematology

Volumn 165, Issue 3, 2014, Pages 300-315

  Castillo, Jorge J ^a   Reagan, John L ^b   Bishop, Kenneth D ^b   Apor, Emmanuel ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

Epstein Barr virus; Human herpesvirus 8; Human T lymphotrophic virus type 1; Lymphoma; Lymphomagenesis

Indexed keywords

BORTEZOMIB; BRENTUXIMAB VEDOTIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CLINICAL PRACTICE; EPSTEIN BARR VIRUS; HEMATOLOGIC MALIGNANCY; HERPES VIRUS; HODGKIN DISEASE; HUMAN; HUMAN HERPESVIRUS 8; LYMPHOPROLIFERATIVE DISEASE; NK T CELL LYMPHOMA; NONHUMAN; PATHOPHYSIOLOGY; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; RISK FACTOR; T CELL LYMPHOMA; VIRAL LYMPHOMAGENESIS; VIRUS INFECTION;

EPSTEIN-BARR VIRUS; HUMAN HERPESVIRUS 8; HUMAN T-LYMPHOTROPHIC VIRUS TYPE 1; LYMPHOMA; LYMPHOMAGENESIS;

ANIMALS; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; LYMPHOMA;

EID: 84898417316     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12788     Document Type: Article

References (153)

1. Advani, A., Coiffier, B., Czuczman, M.S., Dreyling, M., Foran, J., Gine, E., Gisselbrecht, C., Ketterer, N., Nasta, S., Rohatiner, A., Schmidt-Wolf, I.G., Schuler, M., Sierra, J., Smith, M.R., Verhoef, G., Winter, J.N., Boni, J., Vandendries, E., Shapiro, M. & Fayad, L. (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. Journal of Clinical Oncology, 28, 2085-2093.
2. Ai, W.Z., Chang, E.T., Fish, K., Fu, K., Weisenburger, D.D. & Keegan, T.H. (2012) Racial patterns of extranodal natural killer/T-cell lymphoma, nasal type, in California: a population-based study. British Journal of Haematology, 156, 626-632.
3. Alduaij, A., Butera, J.N., Treaba, D. & Castillo, J. (2010) Complete remission in two cases of adult T-cell leukemia/lymphoma treated with hyper-CVAD: a case report and review of the literature. Clinical Lymphoma, Myeloma & Leukemia, 10, 480-483.
4. Alexander, D.D., Mink, P.J., Adami, H.O., Chang, E.T., Cole, P., Mandel, J.S. & Trichopoulos, D. (2007) The non-Hodgkin lymphomas: a review of the epidemiologic literature. International Journal of Cancer, 120, 1-39.
5. An, J., Sun, Y., Fisher, M. & Rettig, M.B. (2004) Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia, 18, 1699-1704.
6. Aoki, Y., Feldman, G.M. & Tosato, G. (2003) Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood, 101, 1535-1542.
7. Au, W.Y., Weisenburger, D.D., Intragumtornchai, T., Nakamura, S., Kim, W.S., Sng, I., Vose, J., Armitage, J.O., Liang, R. & International Peripheral TCLP (2009) Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood, 113, 3931-3937.
8. Azran, I., Schavinsky-Khrapunsky, Y. & Aboud, M. (2004) Role of Tax protein in human T-cell leukemia virus type-I leukemogenicity. Retrovirology, 1, 20.
9. Ballestas, M.E., Chatis, P.A. & Kaye, K.M. (1999) Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science, 284, 641-644.
10. Bassan, R. (2012) Toward victory in adult ALL: blinatumomab joins in. Blood, 120, 5094-5095.
11. Bazarbachi, A., Plumelle, Y., Carlos Ramos, J., Tortevoye, P., Otrock, Z., Taylor, G., Gessain, A., Harrington, W., Panelatti, G. & Hermine, O. (2010) Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. Journal of Clinical Oncology, 28, 4177-4183.
12. Beltran, B.E., Castillo, J.J., Morales, D., de Mendoza, F.H., Quinones, P., Miranda, R.N., Gallo, A., Lopez-Ilasaca, M., Butera, J.N. & Sotomayor, E.M. (2011a) EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru. American Journal of Hematology, 86, 663-667.
13. Beltran, B., Quinones, P., Morales, D., Cotrina, E. & Castillo, J.J. (2011b) Different prognostic factors for survival in acute and lymphomatous adult T-cell leukemia/lymphoma. Leukemia Research, 35, 334-339.
14. Bhatt, S., Ashlock, B.M., Natkunam, Y., Sujoy, V., Chapman, J.R., Ramos, J.C., Mesri, E.A. & Lossos, I.S. (2013a) CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood, 122, 1233-1242.
15. Bhatt, S., Ashlock, B.M., Toomey, N.L., Diaz, L.A., Mesri, E.A., Lossos, I.S. & Ramos, J.C. (2013b) Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma. Journal of Clinical Investigation, 123, 2616-2628.
16. Boulanger, E., Gerard, L., Gabarre, J., Molina, J.M., Rapp, C., Abino, J.F., Cadranel, J., Chevret, S. & Oksenhendler, E. (2005) Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. Journal of Clinical Oncology, 23, 4372-4380.
17. Boulanger, E., Meignin, V. & Oksenhendler, E. (2008) Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma. British Journal of Haematology, 141, 559-561.
18. Braun, M., Melchers, I., Peter, H.H. & Illges, H. (1998) Human B and T lymphocytes have similar amounts of CD21 mRNA, but differ in surface expression of the CD21 glycoprotein. International Immunology, 10, 1197-1202.
19. Bultema, R., Longnecker, R. & Swanson-Mungerson, M. (2009) Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis. Oncogene, 28, 1471-1476.
20. Cairo, M.S. & Bishop, M. (2004) Tumour lysis syndrome: new therapeutic strategies and classification. British Journal of Haematology, 127, 3-11.
21. Carnahan, J., Wang, P., Kendall, R., Chen, C., Hu, S., Boone, T., Juan, T., Talvenheimo, J., Montestruque, S., Sun, J., Elliott, G., Thomas, J., Ferbas, J., Kern, B., Briddell, R., Leonard, J.P. & Cesano, A. (2003) Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clinical Cancer Research, 9, 3982S-3990S.
22. Castillo, J.J., Shum, H., Lahijani, M., Winer, E.S. & Butera, J.N. (2012) Prognosis in primary effusion lymphoma is associated with the number of body cavities involved. Leukaemia & Lymphoma, 53, 2378-2382.
23. Castillo, J.J., Winer, E.S. & Olszewski, A.J. (2013) Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis of the Surveillance, Epidemiology and End Results database. Cancer, 119, 3672-3679.
24. Cesarman, E., Chang, Y., Moore, P.S., Said, J.W. & Knowles, D.M. (1995) Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. New England Journal of Medicine, 332, 1186-1191.
25. Chang, Y., Cesarman, E., Pessin, M.S., Lee, F., Culpepper, J., Knowles, D.M. & Moore, P.S. (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science, 266, 1865-1869.
26. Chen, Y.B., Rahemtullah, A. & Hochberg, E. (2007) Primary effusion lymphoma. The Oncologist, 12, 569-576.
27. Cheng, E.H., Nicholas, J., Bellows, D.S., Hayward, G.S., Guo, H.G., Reitz, M.S. & Hardwick, J.M. (1997) A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proceedings of the National Academy of Sciences of the United States of America, 94, 690-694.
28. Cheung, M.M., Chan, J.K., Lau, W.H., Ngan, R.K. & Foo, W.W. (2002) Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. International Journal of Radiation Oncology Biology Physics, 54, 182-190.
29. Chiang, A.K., Chan, A.C., Srivastava, G. & Ho, F.C. (1997) Nasal T/natural killer (NK)-cell lymphomas are derived from Epstein-Barr virus-infected cytotoxic lymphocytes of both NK- and T-cell lineage. International Journal of Cancer, 73, 332-338.
30. Chim, C.S., Ma, S.Y., Au, W.Y., Choy, C., Lie, A.K., Liang, R., Yau, C.C. & Kwong, Y.L. (2004) Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood, 103, 216-221.
31. Chugh, P., Matta, H., Schamus, S., Zachariah, S., Kumar, A., Richardson, J.A., Smith, A.L. & Chaudhary, P.M. (2005) Constitutive NF-kappaB activation, normal Fas-induced apoptosis, and increased incidence of lymphoma in human herpes virus 8 K13 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 102, 12885-12890.
32. Clybouw, C., McHichi, B., Mouhamad, S., Auffredou, M.T., Bourgeade, M.F., Sharma, S., Leca, G. & Vazquez, A. (2005) EBV infection of human B lymphocytes leads to down-regulation of Bim expression: relationship to resistance to apoptosis. Journal of Immunology, 175, 2968-2973.
33. Comoli, P., Labirio, M., Basso, S., Baldanti, F., Grossi, P., Furione, M., Vigano, M., Fiocchi, R., Rossi, G., Ginevri, F., Gridelli, B., Moretta, A., Montagna, D., Locatelli, F., Gerna, G. & Maccario, R. (2002) Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood, 99, 2592-2598.
34. Costa, L.J., Xavier, A.C., Wahlquist, A.E. & Hill, E.G. (2013) Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood, 121, 4861-4866.
35. DiJoseph, J.F., Armellino, D.C., Boghaert, E.R., Khandke, K., Dougher, M.M., Sridharan, L., Kunz, A., Hamann, P.R., Gorovits, B., Udata, C., Moran, J.K., Popplewell, A.G., Stephens, S., Frost, P. & Damle, N.K. (2004) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood, 103, 1807-1814.
36. Dotti, G., Fiocchi, R., Motta, T., Facchinetti, B., Chiodini, B., Borleri, G.M., Gavazzeni, G., Barbui, T. & Rambaldi, A. (1999) Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8. Leukemia, 13, 664-670.
37. Doubrovina, E., Oflaz-Sozmen, B., Prockop, S.E., Kernan, N.A., Abramson, S., Teruya-Feldstein, J., Hedvat, C., Chou, J.F., Heller, G., Barker, J.N., Boulad, F., Castro-Malaspina, H., George, D., Jakubowski, A., Koehne, G., Papadopoulos, E.B., Scaradavou, A., Small, T.N., Khalaf, R., Young, J.W. & O'Reilly, R.J. (2012) Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood, 119, 2644-2656.
38. Dukers, N.H. & Rezza, G. (2003) Human herpesvirus 8 epidemiology: what we do and do not know. AIDS, 17, 1717-1730.
39. Egle, A., Harris, A.W., Bouillet, P. & Cory, S. (2004) Bim is a suppressor of Myc-induced mouse B cell leukemia. Proceedings of the National Academy of Sciences of the United States of America, 101, 6164-6169.
40. Epstein, A. (2012) Burkitt lymphoma and the discovery of Epstein-Barr virus. British Journal of Haematology, 156, 777-779.
41. Evens, A.M., David, K.A., Helenowski, I., Nelson, B., Kaufman, D., Kircher, S.M., Gimelfarb, A., Hattersley, E., Mauro, L.A., Jovanovic, B., Chadburn, A., Stiff, P., Winter, J.N., Mehta, J., Van Besien, K., Gregory, S., Gordon, L.I., Shammo, J.M., Smith, E.S. & Smith, S.M. (2010) Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. Journal of Clinical Oncology, 28, 1038-1046.
42. Fayad, L., Offner, F., Smith, M.R., Verhoef, G., Johnson, P., Kaufman, J.L., Rohatiner, A., Advani, A., Foran, J., Hess, G., Coiffier, B., Czuczman, M., Gine, E., Durrant, S., Kneissl, M., Luu, K.T., Hua, S.Y., Boni, J., Vandendries, E. & Dang, N.H. (2013) Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. Journal of Clinical Oncology, 31, 573-583.
43. Ferry, J.A. (2006) Burkitt's lymphoma: cinicopathologic features and differential diagnosis. The Oncologist, 11, 375-383.
44. Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Ferme, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F. & Coiffier, B. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 23, 4117-4126.
45. Fischer, S.F., Bouillet, P., O'Donnell, K., Light, A., Tarlinton, D.M. & Strasser, A. (2007) Proapoptotic BH3-only protein Bim is essential for developmentally programmed death of germinal center-derived memory B cells and antibody-forming cells. Blood, 110, 3978-3984.
46. Fish, K., Chen, J. & Longnecker, R. (2013) Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma. Blood, 123, 530-540.
47. Friborg, J. Jr, Kong, W., Hottiger, M.O. & Nabel, G.J. (1999) p53 inhibition by the LANA protein of KSHV protects against cell death. Nature, 402, 889-894.
48. Giam, C.Z. & Jeang, K.T. (2007) HTLV-1 Tax and adult T-cell leukemia. Frontiers in Bioscience, 12, 1496-1507.
49. Gibson, S.E. & Hsi, E.D. (2009) Epstein-Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype. Human Pathology, 40, 653-661.
50. Gratama, J.W., Oosterveer, M.A., Zwaan, F.E., Lepoutre, J., Klein, G. & Ernberg, I. (1988) Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proceedings of the National Academy of Sciences of the United States of America, 85, 8693-8696.
51. Grulich, A.E. & Vajdic, C.M. (2005) The epidemiology of non-Hodgkin lymphoma. Pathology, 37, 409-419.
52. Haque, T., Wilkie, G.M., Taylor, C., Amlot, P.L., Murad, P., Iley, A., Dombagoda, D., Britton, K.M., Swerdlow, A.J. & Crawford, D.H. (2002) Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet, 360, 436-442.
53. Haque, T., Wilkie, G.M., Jones, M.M., Higgins, C.D., Urquhart, G., Wingate, P., Burns, D., McAulay, K., Turner, M., Bellamy, C., Amlot, P.L., Kelly, D., MacGilchrist, A., Gandhi, M.K., Swerdlow, A.J. & Crawford, D.H. (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood, 110, 1123-1131.
54. Harford, J.B. (2012) Viral infections and human cancers: the legacy of Denis Burkitt. British Journal of Haematology, 156, 709-718.
55. Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. & Bloomfield, C.D. (1999) The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Annals of Oncology, 10, 1419-1432.
56. Hemann, M.T., Bric, A., Teruya-Feldstein, J., Herbst, A., Nilsson, J.A., Cordon-Cardo, C., Cleveland, J.L., Tansey, W.P. & Lowe, S.W. (2005) Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature, 436, 807-811.
57. Herndier, B.G., Shiramizu, B.T., Jewett, N.E., Aldape, K.D., Reyes, G.R. & McGrath, M.S. (1992) Acquired immunodeficiency syndrome-associated T-cell lymphoma: evidence for human immunodeficiency virus type 1-associated T-cell transformation. Blood, 79, 1768-1774.
58. Heslop, H.E., Slobod, K.S., Pule, M.A., Hale, G.A., Rousseau, A., Smith, C.A., Bollard, C.M., Liu, H., Wu, M.F., Rochester, R.J., Amrolia, P.J., Hurwitz, J.L., Brenner, M.K. & Rooney, C.M. (2010) Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood, 115, 925-935.
59. Hodson, A., Crichton, S., Montoto, S., Mir, N., Matutes, E., Cwynarski, K., Kumaran, T., Ardeshna, K.M., Pagliuca, A., Taylor, G.P. & Fields, P.A. (2011) Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma. Journal of Clinical Oncology, 29, 4696-4701.
60. Hoeller, S., Tzankov, A., Pileri, S.A., Went, P. & Dirnhofer, S. (2010) Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Human Pathology, 41, 352-357.
61. Hofscheier, A., Ponciano, A., Bonzheim, I., Adam, P., Lome-Maldonado, C., Vela, T., Cortes, E., Ortiz-Hidalgo, C., Fend, F. & Quintanilla-Martinez, L. (2011) Geographic variation in the prevalence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a comparative analysis of a Mexican and a German population. Modern Pathology, 24, 1046-1054.
62. Hong, J., Park, S., Baek, H.L., Jung, J.H., Kang, I.G., Sym, S.J., Park, J., Ahn, J.Y., Cho, E.K., Kim, S.T., Shin, D.B. & Lee, J.H. (2012) Tumor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK/T-cell lymphoma, nasal type. International Journal of Clinical and Experimental Pathology, 5, 939-947.
63. Huen, D.S., Henderson, S.A., Croom-Carter, D. & Rowe, M. (1995) The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene, 10, 549-560.
64. Imai, S., Nishikawa, J. & Takada, K. (1998) Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. Journal of Virology, 72, 4371-4378.
65. Ishida, T., Joh, T., Uike, N., Yamamoto, K., Utsunomiya, A., Yoshida, S., Saburi, Y., Miyamoto, T., Takemoto, S., Suzushima, H., Tsukasaki, K., Nosaka, K., Fujiwara, H., Ishitsuka, K., Inagaki, H., Ogura, M., Akinaga, S., Tomonaga, M., Tobinai, K. & Ueda, R. (2012) Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. Journal of Clinical Oncology, 30, 837-842.
66. Jaccard, A., Gachard, N., Marin, B., Rogez, S., Audrain, M., Suarez, F., Tilly, H., Morschhauser, F., Thieblemont, C., Ysebaert, L., Devidas, A., Petit, B., de Leval, L., Gaulard, P., Feuillard, J., Bordessoule, D., Hermine, O. & Gela and Intergroup G (2011) Efficacy of l-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood, 117, 1834-1839.
67. Jones, D., Ballestas, M.E., Kaye, K.M., Gulizia, J.M., Winters, G.L., Fletcher, J., Scadden, D.T. & Aster, J.C. (1998) Primary-effusion lymphoma and Kaposi's sarcoma in a cardiac-transplant recipient. New England Journal of Medicine, 339, 444-449.
68. Kanavaros, P., Boulland, M.L., Petit, B., Arnulf, B. & Gaulard, P. (2000) Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression. Leukaemia & Lymphoma, 38, 317-326.
69. Kanemitsu, N., Isobe, Y., Masuda, A., Momose, S., Higashi, M., Tamaru, J., Sugimoto, K. & Komatsu, N. (2012) Expression of Epstein-Barr virus-encoded proteins in extranodal NK/T-cell lymphoma, nasal type (ENKL): differences in biologic and clinical behaviors of LMP1-positive and -negative ENKL. Clinical Cancer Research, 18, 2164-2172.
70. Kanwar, J.R., Kamalapuram, S.K. & Kanwar, R.K. (2013) Survivin signaling in clinical oncology: a multifaceted dragon. Medicinal Research Reviews, 33, 765-789.
71. Karajannis, M.A., Hummel, M., Anagnostopoulos, I. & Stein, H. (1997) Strict lymphotropism of Epstein-Barr virus during acute infectious mononucleosis in nonimmunocompromised individuals. Blood, 89, 2856-2862.
72. Katsuya, H., Yamanaka, T., Ishitsuka, K., Utsunomiya, A., Sasaki, H., Hanada, S., Eto, T., Moriuchi, Y., Saburi, Y., Miyahara, M., Sueoka, E., Uike, N., Yoshida, S., Yamashita, K., Tsukasaki, K., Suzushima, H., Ohno, Y., Matsuoka, H., Jo, T., Suzumiya, J. & Tamura, K. (2012) Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. Journal of Clinical Oncology, 30, 1635-1640.
73. Kawaguchi, A., Orba, Y., Kimura, T., Iha, H., Ogata, M., Tsuji, T., Ainai, A., Sata, T., Okamoto, T., Hall, W.W., Sawa, H. & Hasegawa, H. (2009) Inhibition of the SDF-1alpha-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice. Blood, 114, 2961-2968.
74. Kaye, K.M., Izumi, K.M. & Kieff, E. (1993) Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proceedings of the National Academy of Sciences of the United States of America, 90, 9150-9154.
75. Kern, W.F., Spier, C.M., Hanneman, E.H., Miller, T.P., Matzner, M. & Grogan, T.M. (1992) Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement. Blood, 79, 2432-2437.
76. Kilger, E., Kieser, A., Baumann, M. & Hammerschmidt, W. (1998) Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO Journal, 17, 1700-1709.
77. Kim, S.J., Yoon, D.H., Kang, H.J., Kim, J.S., Park, S.K., Kim, H.J., Lee, J., Ryoo, B.Y., Ko, Y.H., Huh, J., Yang, W.I., Kim, H.K., Min, S.K., Lee, S.S., Do, I.G., Suh, C., Kim, W.S. & Consortium for Improving Survival of Lymphoma i (2012a) Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. European Journal of Cancer, 48, 3223-3231.
78. Kim, Y., Leventaki, V., Bhaijee, F., Jackson, C.C., Medeiros, L.J. & Vega, F. (2012b) Extracavitary/solid variant of primary effusion lymphoma. Annals of Diagnostic Pathology, 16, 441-446.
79. Klepfish, A., Sarid, R., Shtalrid, M., Shvidel, L., Berrebi, A. & Schattner, A. (2001) Primary effusion lymphoma (PEL) in HIV-negative patients-a distinct clinical entity. Leukaemia & Lymphoma, 41, 439-443.
80. Knecht, H., Berger, C., Rothenberger, S., Odermatt, B.F. & Brousset, P. (2001) The role of Epstein-Barr virus in neoplastic transformation. Oncology, 60, 289-302.
81. Kochenderfer, J.N., Dudley, M.E., Carpenter, R.O., Kassim, S.H., Rose, J.J., Telford, W.G., Hakim, F.T., Halverson, D.C., Fowler, D.H., Hardy, N.M., Mato, A.R., Hickstein, D.D., Gea-Banacloche, J.C., Pavletic, S.Z., Sportes, C., Maric, I., Feldman, S.A., Hansen, B.G., Wilder, J.S., Blacklock-Schuver, B., Jena, B., Bishop, M.R., Gress, R.E. & Rosenberg, S.A. (2013) Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood, 122, 4129-4139.
82. Kwong, Y.L. (2011) The diagnosis and management of extranodal NK/T-cell lymphoma, nasal-type and aggressive NK-cell leukemia. Journal of Clinical and Experimental Hematopathology, 51, 21-28.
83. + NK lymphomas: clinicopathological features and prognosis. British Journal of Haematology, 97, 821-829.
84. Law, C.L., Sutherland, M., Miyamoto, J., Hayes, D., Duniho, S., Boursalian, T., Stone, I., Jonas, M., Smith, L. & Benjamin, D. (2011) Preclinical characterization of an auristatin-based anti-CD19 drug conjugate, SGN-19A. Cancer Research, 71, 625.
85. Lee, J., Suh, C., Park, Y.H., Ko, Y.H., Bang, S.M., Lee, J.H., Lee, D.H., Huh, J., Oh, S.Y., Kwon, H.C., Kim, H.J., Lee, S.I., Kim, J.H., Park, J., Oh, S.J., Kim, K., Jung, C., Park, K. & Kim, W.S. (2006) Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. Journal of Clinical Oncology, 24, 612-618.
86. Lee, J., Suh, C., Kang, H.J., Ryoo, B.Y., Huh, J., Ko, Y.H., Eom, H.S., Kim, K., Park, K. & Kim, W.S. (2008) Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Annals of Oncology, 19, 2079-2083.
87. Leoncini, L., Raphael, M., Stein, H., Harris, N.L., Jaffe, E.S. & Kluin, P.M. (2008) Burkitt lymphoma. In: WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues (eds. by S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele & J.W. Vardiman ), pp. 262-264. IARC, Lyon, France.
88. Leucci, E., Onnis, A., Cocco, M., De Falco, G., Imperatore, F., Giuseppina, A., Costanzo, V., Cerino, G., Mannucci, S., Cantisani, R., Nyagol, J., Mwanda, W., Iriso, R., Owang, M., Schurfeld, K., Bellan, C., Lazzi, S. & Leoncini, L. (2010) B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression. International Journal of Cancer, 126, 1316-1326.
89. Li, S., Feng, X., Li, T., Zhang, S., Zuo, Z., Lin, P., Konoplev, S., Bueso-Ramos, C.E., Vega, F., Medeiros, L.J. & Yin, C.C. (2013) Extranodal NK/T-cell lymphoma, nasal type: a report of 73 cases at MD Anderson Cancer Center. American Journal of Surgical Pathology, 37, 14-23.
90. Lim, S.T., Karim, R., Nathwani, B.N., Tulpule, A., Espina, B. & Levine, A.M. (2005a) AIDS-related Burkitt's lymphoma versus diffuse large B-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. Journal of Clinical Oncology, 23, 4430-4438.
91. Lim, S.T., Rubin, N., Said, J. & Levine, A.M. (2005b) Primary effusion lymphoma: successful treatment with highly active antiretroviral therapy and rituximab. Annals of Hematology, 84, 551-552.
92. Liu, X., Wang, B., Ma, X. & Guo, Y. (2009) NF-kappaB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK/T-cell lymphoma, nasal type. Japanese Journal of Clinical Oncology, 39, 418-424.
93. Lu, F., Day, L., Gao, S.J. & Lieberman, P.M. (2006) Acetylation of the latency-associated nuclear antigen regulates repression of Kaposi's sarcoma-associated herpesvirus lytic transcription. Journal of Virology, 80, 5273-5282.
94. Marcos-Villar, L., Lopitz-Otsoa, F., Gallego, P., Munoz-Fontela, C., Gonzalez-Santamaria, J., Campagna, M., Shou-Jiang, G., Rodriguez, M.S. & Rivas, C. (2009) Kaposi's sarcoma-associated herpesvirus protein LANA2 disrupts PML oncogenic domains and inhibits PML-mediated transcriptional repression of the survivin gene. Journal of Virology, 83, 8849-8858.
95. Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E., Catalano, J., Solal-Celigny, P., Offner, F., Walewski, J., Raposo, J., Jack, A. & Smith, P. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105, 1417-1423.
96. Marques, H., Catarino, R., Domingues, N., Barros, E., Portela, C., Almeida, M.I., Costa, S., Reis, R.M., Medeiros, R. & Longatto-Filho, A. (2012) Detection of the Epstein-Barr virus in blood and bone marrow mononuclear cells of patients with aggressive B-cell non-Hodgkin's lymphoma is not associated with prognosis. Oncology Letters, 4, 1285-1289.
97. Matsuoka, M. & Jeang, K.T. (2011) Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene, 30, 1379-1389.
98. Matta, H. & Chaudhary, P.M. (2004) Activation of alternative NF-kappa B pathway by human herpes virus 8-encoded Fas-associated death domain-like IL-1 beta-converting enzyme inhibitory protein (vFLIP). Proceedings of the National Academy of Sciences of the United States of America, 101, 9399-9404.
99. Matta, H. & Chaudhary, P.M. (2005) The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells. Cancer Biology & Therapy, 4, 77-82.
100. Mbulaiteye, S.M., Biggar, R.J., Goedert, J.J. & Engels, E.A. (2002) Pleural and peritoneal lymphoma among people with AIDS in the United States. Journal of Acquired Immune Deficiency Syndromes, 29, 418-421.
101. Montes-Moreno, S., Odqvist, L., Diaz-Perez, J.A., Lopez, A.B., de Villambrosia, S.G., Mazorra, F., Castillo, M.E., Lopez, M., Pajares, R., Garcia, J.F., Mollejo, M., Camacho, F.I., Ruiz-Marcellan, C., Adrados, M., Ortiz, N., Franco, R., Ortiz-Hidalgo, C., Suarez-Gauthier, A., Young, K.H. & Piris, M.A. (2012) EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Modern Pathology, 25, 968-982.
102. Morton, L.M., Wang, S.S., Cozen, W., Linet, M.S., Chatterjee, N., Davis, S., Severson, R.K., Colt, J.S., Vasef, M.A., Rothman, N., Blair, A., Bernstein, L., Cross, A.J., De Roos, A.J., Engels, E.A., Hein, D.W., Hill, D.A., Kelemen, L.E., Lim, U., Lynch, C.F., Schenk, M., Wacholder, S., Ward, M.H., Hoar Zahm, S., Chanock, S.J., Cerhan, J.R. & Hartge, P. (2008) Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood, 112, 5150-5160.
103. Mosialos, G., Birkenbach, M., Yalamanchili, R., VanArsdale, T., Ware, C. & Kieff, E. (1995) The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell, 80, 389-399.
104. Munoz, E. & Israel, A. (1995) Activation of NF-kappa B by the Tax protein of HTLV-1. Immunobiology, 193, 128-136.
105. Nagasawa, T., Nakajima, T., Tachibana, K., Iizasa, H., Bleul, C.C., Yoshie, O., Matsushima, K., Yoshida, N., Springer, T.A. & Kishimoto, T. (1996) Molecular cloning and characterization of a murine pre-B-cell growth-stimulating factor/stromal cell-derived factor 1 receptor, a murine homolog of the human immunodeficiency virus 1 entry coreceptor fusin. Proceedings of the National Academy of Sciences of the United States of America, 93, 14726-14729.
106. Nakamura, S., Jaffe, E.S. & Swerdlow, S.H. (2008) EBV positive diffuse large B-cell lymphoma of the elderly. In: WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues (eds. by S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele & J.W. Vardiman ), pp. 243-244. IARC, Lyon, France.
107. Nakano, K. & Watanabe, T. (2012) HTLV-1 Rex: the courier of viral messages making use of the host vehicle. Frontiers in Microbiology, 3, 330.
108. Nemerow, G.R., Wolfert, R., McNaughton, M.E. & Cooper, N.R. (1985) Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). Journal of Virology, 55, 347-351.
109. Niedermeier, A., Talanin, N., Chung, E.J., Sells, R.E., Borris, D.L., Orenstein, J.M., Trepel, J.B. & Blauvelt, A. (2006) Histone deacetylase inhibitors induce apoptosis with minimal viral reactivation in cells infected with Kaposi's sarcoma-associated herpesvirus. The Journal of Investigative Dermatology, 126, 2516-2524.
110. Ohshima, K., Jaffee, E. & Kikuchi, M. (2008) Adult T-cell leukaemia/lymphoma. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (eds. by S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Jaffe, H. Stein, J. Thiele & J.W. Vardiman ), pp. 116-145. IARC, Lyon, France.
111. Ok, C.Y., Papathomas, T.G., Medeiros, L.J. & Young, K.H. (2013) EBV-positive diffuse large B-cell lymphoma of the elderly. Blood, 122, 328-340.
112. Oyama, T., Yamamoto, K., Asano, N., Oshiro, A., Suzuki, R., Kagami, Y., Morishima, Y., Takeuchi, K., Izumo, T., Mori, S., Ohshima, K., Suzumiya, J., Nakamura, N., Abe, M., Ichimura, K., Sato, Y., Yoshino, T., Naoe, T., Shimoyama, Y., Kamiya, Y., Kinoshita, T. & Nakamura, S. (2007) Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clinical Cancer Research, 13, 5124-5132.
113. Park, S., Lee, J., Ko, Y.H., Han, A., Jun, H.J., Lee, S.C., Hwang, I.G., Park, Y.H., Ahn, J.S., Jung, C.W., Kim, K., Ahn, Y.C., Kang, W.K., Park, K. & Kim, W.S. (2007) The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood, 110, 972-978.
114. Perez, C.L. & Rudoy, S. (2001) Anti-CD20 monoclonal antibody treatment of human herpesvirus 8-associated, body cavity-based lymphoma with an unusual phenotype in a human immunodeficiency virus-negative patient. Clinical and Diagnostic Laboratory Immunology, 8, 993-996.
115. Perrine, S.P., Hermine, O., Small, T., Suarez, F., O'Reilly, R., Boulad, F., Fingeroth, J., Askin, M., Levy, A., Mentzer, S.J., Di Nicola, M., Gianni, A.M., Klein, C., Horwitz, S. & Faller, D.V. (2007) A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood, 109, 2571-2578.
116. Pfreundschuh, M., Kuhnt, E., Trumper, L., Osterborg, A., Trneny, M., Shepherd, L., Gill, D.S., Walewski, J., Pettengell, R., Jaeger, U., Zinzani, P.L., Shpilberg, O., Kvaloy, S., de Nully Brown, P., Stahel, R., Milpied, N., Lopez-Guillermo, A., Poeschel, V., Grass, S., Loeffler, M., Murawski, N. & MabThera International Trial G (2011) CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. The Lancet Oncology, 12, 1013-1022.
117. Poiesz, B.J., Ruscetti, F.W., Reitz, M.S., Kalyanaraman, V.S. & Gallo, R.C. (1981) Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sezary T-cell leukaemia. Nature, 294, 268-271.
118. Pongpruttipan, T., Kummalue, T., Bedavanija, A., Khuhapinant, A., Ohshima, K., Arakawa, F., Niino, D. & Sukpanichnant, S. (2011) Aberrant antigenic expression in extranodal NK/T-cell lymphoma: a multi-parameter study from Thailand. Diagnostic Pathology, 6, 79.
119. Porter, D.L., Levine, B.L., Kalos, M., Bagg, A. & June, C.H. (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New England Journal of Medicine, 365, 725-733.
120. Punj, V., Matta, H. & Chaudhary, P.M. (2012) A computational profiling of changes in gene expression and transcription factors induced by vFLIP K13 in primary effusion lymphoma. PLoS ONE, 7, e37498.
121. Raff, T., Gokbuget, N., Luschen, S., Reutzel, R., Ritgen, M., Irmer, S., Bottcher, S., Horst, H.A., Kneba, M., Hoelzer, D., Bruggemann, M. & Group GS (2007) Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood, 109, 910-915.
122. Roncador, G., Garcia, J.F., Garcia, J.F., Maestre, L., Lucas, E., Menarguez, J., Ohshima, K., Nakamura, S., Banham, A.H. & Piris, M.A. (2005) FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. Leukemia, 19, 2247-2253.
123. Said, J. & Cesarman, E. (2008) Primary effusion lymphoma. In: WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues (eds. by S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele & J.W. Vardiman ), pp. 260-261. IARC, Lyon, France.
124. Savoldo, B., Goss, J.A., Hammer, M.M., Zhang, L., Lopez, T., Gee, A.P., Lin, Y.F., Quiros-Tejeira, R.E., Reinke, P., Schubert, S., Gottschalk, S., Finegold, M.J., Brenner, M.K., Rooney, C.M. & Heslop, H.E. (2006) Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood, 108, 2942-2949.
125. Shen, L., Au, W.Y., Guo, T., Wong, K.Y., Wong, M.L., Tsuchiyama, J., Yuen, P.W., Kwong, Y.L., Liang, R.H. & Srivastava, G. (2007) Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation. Blood, 110, 469-470.
126. Shiramizu, B., Herndier, B.G. & McGrath, M.S. (1994) Identification of a common clonal human immunodeficiency virus integration site in human immunodeficiency virus-associated lymphomas. Cancer Research, 54, 2069-2072.
127. Siddiqi, T. & Joyce, R.M. (2008) A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab. Clinical Lymphoma & Myeloma, 8, 300-304.
128. Simonelli, C., Spina, M., Cinelli, R., Talamini, R., Tedeschi, R., Gloghini, A., Vaccher, E., Carbone, A. & Tirelli, U. (2003) Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. Journal of Clinical Oncology, 21, 3948-3954.
129. Sixbey, J.W., Nedrud, J.G., Raab-Traub, N., Hanes, R.A. & Pagano, J.S. (1984) Epstein-Barr virus replication in oropharyngeal epithelial cells. New England Journal of Medicine, 310, 1225-1230.
130. Suzumiya, J., Ohshima, K., Tamura, K., Karube, K., Uike, N., Tobinai, K., Gascoyne, R.D., Vose, J.M., Armitage, J.O., Weisenburger, D.D. & International Peripheral TCLP (2009) The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project. Annals of Oncology, 20, 715-721.
131. Swanton, C., Mann, D.J., Fleckenstein, B., Neipel, F., Peters, G. & Jones, N. (1997) Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature, 390, 184-187.
132. Swerdlow, S.H., Webber, S.A., Chadburn, A. & Ferry, J.A. (2008) Post-transplant lymphoproliferative disorders. In: WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues (eds. by S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele & J.W. Vardiman ), pp. 343-349. IARC, Lyon, France.
133. Takahashi, E., Ohshima, K., Kimura, H., Hara, K., Suzuki, R., Kawa, K., Eimoto, T., Nakamura, S. & Group NK-cTS (2011) Clinicopathological analysis of the age-related differences in patients with Epstein-Barr virus (EBV)-associated extranasal natural killer (NK)/T-cell lymphoma with reference to the relationship with aggressive NK cell leukaemia and chronic active EBV infection-associated lymphoproliferative disorders. Histopathology, 59, 660-671.
134. Takao, T., Kobayashi, Y., Kuroda, J., Omoto, A., Nishimura, T., Kamitsuji, Y., Fukiya, E., Nakamura, C., Kimura, S. & Yoshikawa, T. (2004) Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis. American Journal of Hematology, 77, 419-420.
135. Thompson, M.P. & Kurzrock, R. (2004) Epstein-Barr virus and cancer. Clinical Cancer Research, 10, 803-821.
136. Topp, M.S., Gokbuget, N., Zugmaier, G., Degenhard, E., Goebeler, M.E., Klinger, M., Neumann, S.A., Horst, H.A., Raff, T., Viardot, A., Stelljes, M., Schaich, M., Kohne-Volland, R., Bruggemann, M., Ottmann, O.G., Burmeister, T., Baeuerle, P.A., Nagorsen, D., Schmidt, M., Einsele, H., Riethmuller, G., Kneba, M., Hoelzer, D., Kufer, P. & Bargou, R.C. (2012) Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood, 120, 5185-5187.
137. Toulza, F., Nosaka, K., Takiguchi, M., Pagliuca, T., Mitsuya, H., Tanaka, Y., Taylor, G.P. & Bangham, C.R. (2009) FoxP3+ regulatory T cells are distinct from leukemia cells in HTLV-1-associated adult T-cell leukemia. International Journal of Cancer, 125, 2375-2382.
138. Tsukasaki, K. & Tobinai, K. (2012) Clinical trials and treatment of ATL. Leukemia Research and Treatment, 2012, 101754.
139. Tsukasaki, K., Utsunomiya, A., Fukuda, H., Shibata, T., Fukushima, T., Takatsuka, Y., Ikeda, S., Masuda, M., Nagoshi, H., Ueda, R., Tamura, K., Sano, M., Momita, S., Yamaguchi, K., Kawano, F., Hanada, S., Tobinai, K., Shimoyama, M., Hotta, T., Tomonaga, M. & Japan Clinical Oncology Group Study J (2007) VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. Journal of Clinical Oncology, 25, 5458-5464.
140. Tsukasaki, K., Hermine, O., Bazarbachi, A., Ratner, L., Ramos, J.C., Harrington, W. Jr, O'Mahony, D., Janik, J.E., Bittencourt, A.L., Taylor, G.P., Yamaguchi, K., Utsunomiya, A., Tobinai, K. & Watanabe, T. (2009) Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. Journal of Clinical Oncology, 27, 453-459.
141. Uenogawa, K., Hatta, Y., Arima, N., Hayakawa, S., Sawada, U., Aizawa, S., Yamamoto, T. & Takeuchi, J. (2011) Azacitidine induces demethylation of p16INK4a and inhibits growth in adult T-cell leukemia/lymphoma. International Journal of Molecular Medicine, 28, 835-839.
142. Vereide, D.T. & Sugden, B. (2011) Lymphomas differ in their dependence on Epstein-Barr virus. Blood, 117, 1977-1985.
143. Vose, J., Armitage, J., Weisenburger, D. & for the International T-Cell Lymphoma Project (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. Journal of Clinical Oncology, 26, 4124-4130.
144. Wu, X., Li, P., Zhao, J., Yang, X., Wang, F., Yang, Y.Q., Fang, F., Xu, Y., Zhang, H., Wang, W.Y. & Yi, C. (2008) A clinical study of 115 patients with extranodal natural killer/T-cell lymphoma, nasal type. Clinical Oncology (Royal College of Radiologists (Great Britain)), 20, 619-625.
145. Yamaguchi, M., Suzuki, R., Kwong, Y.L., Kim, W.S., Hasegawa, Y., Izutsu, K., Suzumiya, J., Okamura, T., Nakamura, S., Kawa, K. & Oshimi, K. (2008) Phase I study of dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Science, 99, 1016-1020.
146. Yamaguchi, M., Kwong, Y.L., Kim, W.S., Maeda, Y., Hashimoto, C., Suh, C., Izutsu, K., Ishida, F., Isobe, Y., Sueoka, E., Suzumiya, J., Kodama, T., Kimura, H., Hyo, R., Nakamura, S., Oshimi, K. & Suzuki, R. (2011) Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. Journal of Clinical Oncology, 29, 4410-4416.
147. Yan, P., Fu, J., Qu, Z., Li, S., Tanaka, T., Grusby, M.J. & Xiao, G. (2009a) PDLIM2 suppresses human T-cell leukemia virus type I Tax-mediated tumorigenesis by targeting Tax into the nuclear matrix for proteasomal degradation. Blood, 113, 4370-4380.
148. Yan, P., Qu, Z., Ishikawa, C., Mori, N. & Xiao, G. (2009b) Human T-cell leukemia virus type I-mediated repression of PDZ-LIM domain-containing protein 2 involves DNA methylation but independent of the viral oncoprotein tax. Neoplasia, 11, 1036-1041.
149. Yasunaga, J., Taniguchi, Y., Nosaka, K., Yoshida, M., Satou, Y., Sakai, T., Mitsuya, H. & Matsuoka, M. (2004) Identification of aberrantly methylated genes in association with adult T-cell leukemia. Cancer Research, 64, 6002-6009.
150. Younes, A., Bartlett, N.L., Leonard, J.P., Kennedy, D.A., Lynch, C.M., Sievers, E.L. & Forero-Torres, A. (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. New England Journal of Medicine, 363, 1812-1821.
151. Young, K.H., Visco, C., Ok, C.Y., Tzankov, A., Dybkaer, K., Orazi, A., Bhagat, G., Hsi, E.D., van Krieken, J.H., D' Amore, E.S.G., Ponzoni, M., Ferreri, A.J.M., Winter, J.N., Go, R.S., Piris, M.A., Moller, M.B. & Medeiros, L.J. (2013) Epstein-Barr virus (EBV) positive diffuse large B-cell lymphoma is a neoplasm with preferential activated gene expression signature whose outcome relies on CD30 expression: A report from the International DLBCL Rituximab-CHOP Consortium Program Study. 12th International Conference on Malignant Lymphoma, Lugano, Switzerland.
152. Zimmerman, B., Sargeant, A., Landes, K., Fernandez, S.A., Chen, C.S. & Lairmore, M.D. (2011) Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma. Leukemia Research, 35, 1491-1497.
153. Zou, P., Kawada, J., Pesnicak, L. & Cohen, J.I. (2007) Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. Journal of Virology, 81, 10029-10036.